Europäische Union - Schwedisch - EMA (European Medicines Agency)

zentiva, k.s. - pregabalin - anxiety disorders; epilepsy - antiepileptika, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinuri, paroxysmal - immunsuppressiva - soliris är indicerat hos vuxna och barn för behandling av:paroxysmal nattlig haemoglobinuria (pnh). bevis på klinisk nytta som är visat att patienter med hemolys med kliniska symptom(s) tyder på en hög sjukdomsaktivitet, oavsett transfusion historia (se avsnitt 5. atypiska hemolytisk uremiskt syndrom (åhus). soliris är indicerat hos vuxna för behandling av:refraktära generaliserade myasthenia gravis (gmg) hos patienter som är anti-acetylkolin-receptorn (achr) antikropp-positiva (se avsnitt 5. neuromyelitis optica spectrum disorder (nmosd) hos patienter som är anti-akvaporin-4 (aqp4) antikropp-positiv med ett skovvis förlopp sjukdomen.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslikarbazepinacetat - epilepsi - antiepileptika, - zebinix är indicerat som tilläggsbehandling hos vuxna, ungdomar och barn i åldern över 6 år, med partiella anfall med eller utan sekundär generalisering.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

mylan pharmaceuticals limited - zonisamid - epilepsi - antiepileptika, - monoterapi vid behandling av partiella anfall med eller utan sekundär generalisering hos vuxna med nydiagnostiserad epilepsi, tilläggsbehandling vid behandling av partiella anfall med eller utan sekundär generalisering hos vuxna, ungdomar och barn i åldern 6 år och uppåt.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakosamid - epilepsi - antiepileptika, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektiva immunsuppressiva medel - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

ucb pharma s.a. - lakosamid - epilepsier, delvis - antiepileptika, - lacosamide ucb är indicerat som monoterapi och som tilläggsbehandling vid behandling av partiella anfall med eller utan sekundär generalisering hos vuxna, ungdomar och barn från 4 års ålder med epilepsi.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graftförkastning - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - immunsuppressiva - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasis - immunsuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.